Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.
about
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathwayAbiraterone in metastatic prostate cancer without previous chemotherapyHormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerProgress of molecular targeted therapies for prostate cancersAbiraterone in prostate cancer: a new angle to an old problemCancer wars: natural products strike backRecent progress in pharmaceutical therapies for castration-resistant prostate cancerKetoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrationsAbiraterone and increased survival in metastatic prostate cancerSodium Bis(2-methoxyethoxy)aluminum HydrideThe Concise Guide to PHARMACOLOGY 2013/14: enzymes.Potential strategies for increasing drug-discovery productivity.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study.A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer.Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats.Noncanonical mechanisms to regulate nuclear receptor signaling.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Novel drugs targeting the androgen receptor pathway in prostate cancer.Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committInhibition of CYP 17, a new strategy for the treatment of prostate cancer.A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.Metastatic castration-resistant prostate cancer: two case reports of dramatic response with abiraterone acetate in patients heavily pretreated with chemotherapy.Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancerRhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case reportCastration-resistant prostate cancer: mechanisms, targets, and treatment.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceSelective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
P2860
Q24603649-4C8A0D25-54AB-430A-BB0E-0DB5CB4A225AQ24612084-C4BDD087-14F4-4443-93C3-44EEE455294AQ24646000-5B9DEB14-19C5-4755-BE4B-0C709176043BQ26750620-744E3FB1-DFFD-4855-A992-7E5716D63B3AQ26823014-2160E59A-93F4-4324-9C43-F88BF1DE5DC8Q26828810-5FA6A1C5-6B25-45B0-AE5E-252CD1C39C27Q26850074-1729E945-0DF5-481D-B5A2-EBDF6977148DQ27022567-EF2D473A-5A36-486A-A35D-84097BA476B3Q28539116-504CC48D-89F1-4C53-9A3C-917E248A26DEQ29617512-C577CF4F-813B-4717-AD03-6A0AE8E4403AQ30049241-F3F688B0-E8F6-4748-9FAC-242E9DBD7BA4Q30486745-26C21870-EE98-4872-A885-2BA6A1F68DA4Q31154360-6EDDD6E9-4A44-4FE6-8F34-81A55491F861Q33621403-84B1EBCE-729E-4A35-9C41-75E823F4E6F0Q33696276-B9150B5E-2F42-459D-9AD4-546108995204Q33998980-551E4061-8F34-4CD5-9FF8-4E0658CF5CBAQ34048805-EE9CD1A3-6021-4D1B-BD75-4D72080FAE17Q34183632-8829C6BD-3C80-4A94-A1C3-09C242799671Q34294888-F92DEF53-AB3E-4BF7-B79D-8DB979562B2CQ34327168-AC305986-4B6F-4DCA-BE27-7E713D7BB9DFQ34338685-4FE2A7FD-5042-4D3B-A196-A7AF25BFF607Q34387852-9C992FA6-7D1C-4DB9-9354-D15A446F4635Q34395777-358F34B8-F40E-422D-B745-C52EE2E52EEFQ34467551-BFC0E6DE-2162-4E4B-AD31-842BF6E3559FQ34522279-C9290D93-2865-45CD-BF56-7B22DF4E465FQ34604646-73DF2AC8-8BC0-4594-8994-1C8CEEB8AB78Q34655529-96803CE0-F090-4254-9B0F-C9B47E0AA31AQ34733099-2983715D-0F29-438D-A6CD-DDF6E6D608D6Q34746876-D32090C7-9C3E-4CB0-AAC0-54C1074E114CQ34778772-317FF45E-A253-4897-A67E-CBAB999049D4Q34880412-AFDD7903-E0FF-438A-A7BF-92E0A00FBA41Q35128716-52F2A427-7A5F-448A-AF84-F50848CBE6D9Q35209369-9233707C-8767-4196-B123-5C7086AA5D68Q35358010-88C03796-1CE8-4654-929D-CBBDD89CD7FAQ35713138-8978CB58-839C-46AE-826D-F08123DC737DQ35721588-BE0A04ED-6806-41A7-87E8-E20C97F5586CQ35864027-9F4D865D-9583-4A6C-8CAC-69A52A30251BQ36398998-43B5489A-9652-4465-ACA3-5C8B4CDA4B44Q36470627-E7ECF7A0-42F1-4583-B9A4-CE96B97AA573Q36504117-17F79C96-9FFB-4FA0-85B9-DBEE4CC4D191
P2860
Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Novel steroidal inhibitors of ...... treatment of prostatic cancer.
@en
Novel steroidal inhibitors of ...... treatment of prostatic cancer.
@nl
type
label
Novel steroidal inhibitors of ...... treatment of prostatic cancer.
@en
Novel steroidal inhibitors of ...... treatment of prostatic cancer.
@nl
prefLabel
Novel steroidal inhibitors of ...... treatment of prostatic cancer.
@en
Novel steroidal inhibitors of ...... treatment of prostatic cancer.
@nl
P2093
P356
P1476
Novel steroidal inhibitors of ...... treatment of prostatic cancer.
@en
P2093
G A Potter
M G Rowlands
S E Barrie
P304
P356
10.1021/JM00013A022
P407
P577
1995-06-01T00:00:00Z